Clinical background of the AML patients with FLT3-ITD
| . | All (N = 147) . | AR . | . | |
|---|---|---|---|---|
| <0.5 (n = 59) . | ≥0.5 (n = 88) . | P . | ||
| Age, median (range), y | 56 (18-90) | 54 (21-86) | 54 (18-90) | .853 |
| Sex | .172 | |||
| Male | 66 | 30 | 36 | |
| Female | 77 | 26 | 51 | |
| Unknown | 4 | 3 | 1 | |
| ECOG-PS, 0/1/2/3/4 | 41/46/6/3/3 | 21/17/1/1/0 | 20/29/5/2/3 | |
| WBC count, median (range), ×109/L | 56.1 (1.0-677.0) | 47.2 (1.0-620.0) | 75.6 (1.3-677.0) | .342 |
| Hb, median (range), g/dL | 8.4 (3.3-15.1) | 8.4 (3.3-15.0) | 8.6 (4.1-15.1) | .799 |
| Plt count, median (range), ×109/L | 50.0 (5.0-630.0) | 55.0 (6.0-630.0) | 49.0 (5.0-540.0) | .515 |
| LDH, median (range), IU/L | 719 (151-5930) | 718 (151-5930) | 765 (156-4144) | .437 |
| FAB | ||||
| M0 | 6 | 1 | 5 | .402 |
| M1 | 51 | 17 | 34 | .220 |
| M2 | 37 | 19 | 18 | .108 |
| M4 | 29 | 13 | 16 | .565 |
| M5 | 17 | 4 | 13 | .190 |
| Not determined | 7 | 5 | 2 | .117 |
| Chromosomal aberrations | ||||
| t(8,21) | 4 | 2 | 2 | 1.000 |
| inv(16) | 1 | 1 | 0 | .401 |
| Normal | 106 | 40 | 66 | .354 |
| Trisomy 8 | 3 | 0 | 3 | .274 |
| 11q23 | 0 | 0 | 0 | 1.000 |
| Complex | 4 | 1 | 3 | .649 |
| Unknown | 8 | 4 | 4 | .558 |
| Gene mutation | ||||
| FLT3-TKD | 0 | 0 | 0 | 1.000 |
| NPM1 | 83 | 31 | 52 | .432 |
| CEBPA(sm) | 8 | 5 | 3 | .268 |
| CEBPA(dm) | 3 | 3 | 0 | .063 |
| Induction therapy | ||||
| (IDA/DNR/ACR) + Ara-C | 108 | 41 | 67 | .371 |
| AVVV, BHAC-DM, CAG | 25 | 12 | 13 | .382 |
| Others | 14 | 6 | 8 | .827 |
| Stem cell transplantation | ||||
| All | 65 | 26 | 39 | .976 |
| In CR1 | 31 | 16 | 15 | .142 |
| . | All (N = 147) . | AR . | . | |
|---|---|---|---|---|
| <0.5 (n = 59) . | ≥0.5 (n = 88) . | P . | ||
| Age, median (range), y | 56 (18-90) | 54 (21-86) | 54 (18-90) | .853 |
| Sex | .172 | |||
| Male | 66 | 30 | 36 | |
| Female | 77 | 26 | 51 | |
| Unknown | 4 | 3 | 1 | |
| ECOG-PS, 0/1/2/3/4 | 41/46/6/3/3 | 21/17/1/1/0 | 20/29/5/2/3 | |
| WBC count, median (range), ×109/L | 56.1 (1.0-677.0) | 47.2 (1.0-620.0) | 75.6 (1.3-677.0) | .342 |
| Hb, median (range), g/dL | 8.4 (3.3-15.1) | 8.4 (3.3-15.0) | 8.6 (4.1-15.1) | .799 |
| Plt count, median (range), ×109/L | 50.0 (5.0-630.0) | 55.0 (6.0-630.0) | 49.0 (5.0-540.0) | .515 |
| LDH, median (range), IU/L | 719 (151-5930) | 718 (151-5930) | 765 (156-4144) | .437 |
| FAB | ||||
| M0 | 6 | 1 | 5 | .402 |
| M1 | 51 | 17 | 34 | .220 |
| M2 | 37 | 19 | 18 | .108 |
| M4 | 29 | 13 | 16 | .565 |
| M5 | 17 | 4 | 13 | .190 |
| Not determined | 7 | 5 | 2 | .117 |
| Chromosomal aberrations | ||||
| t(8,21) | 4 | 2 | 2 | 1.000 |
| inv(16) | 1 | 1 | 0 | .401 |
| Normal | 106 | 40 | 66 | .354 |
| Trisomy 8 | 3 | 0 | 3 | .274 |
| 11q23 | 0 | 0 | 0 | 1.000 |
| Complex | 4 | 1 | 3 | .649 |
| Unknown | 8 | 4 | 4 | .558 |
| Gene mutation | ||||
| FLT3-TKD | 0 | 0 | 0 | 1.000 |
| NPM1 | 83 | 31 | 52 | .432 |
| CEBPA(sm) | 8 | 5 | 3 | .268 |
| CEBPA(dm) | 3 | 3 | 0 | .063 |
| Induction therapy | ||||
| (IDA/DNR/ACR) + Ara-C | 108 | 41 | 67 | .371 |
| AVVV, BHAC-DM, CAG | 25 | 12 | 13 | .382 |
| Others | 14 | 6 | 8 | .827 |
| Stem cell transplantation | ||||
| All | 65 | 26 | 39 | .976 |
| In CR1 | 31 | 16 | 15 | .142 |
Data are numbers of patients, except as noted. Some data are missing due to the unavailability of certain follow-up data in a retrospective study.
ACR, aclarubicin; Ara-C, cytarabine; AVVV, cytarabine + etoposide + vincristine + vinblastine; BHAC-D, enocitabine + daunorubicin + 6-mercaptopurine; CAG, cytarabine + cytarabine + granulocyte colony-stimulating factor; dm, double mutation; DNR, daunorubicin; ECOG-PS, Eastern Cooperative Oncology Group performance status; FLT3-TKD, fms-like kinase 3-tyrosine kinase domain; IDA, idarubicin; Plt, platelet; sm, single mutation; WBC, white blood cell.